TABLE 4.

Sensitivity, specificity, PPV, and NPV of 14-Gene-Panel, PSA, and Gleason score for diagnosis of higher-risk and lower-risk PCa in Gleason scores 6 and 7 patients in a prospective PCa urine cohort.

	14-gene panel			PSA			Gleason score
	Positive	Negative	Total	Positive	Negative	Total	Positive	Negative	Total
Higher risk	68	14	82	35	47	82	71	11	82
Lower risk	10	40	50	0	49	49	13	37	50
Total	78	54	132	35	96	131	84	48	132
Sensitivity (95% CI)	82.93 (91.07–74.78)%			42.68 (53.39–31.98)%			86.59 (93.96–79.21)%
Specificity (95% CI)	80.00 (91.09–68.91)%			100 (100–100)%			74.00 (86.16–61.84)%
PPV (95% CI)	87.18 (94.60–79.76)%			100 (100–100)%			84.52 (92.26–76.79)%
NPV (95% CI)	74.07 (85.76–62.39)%			51.04 (61.04–41.04)%			77.08 (88.97–65.19)%